Related Experiment Video
Updated: Apr 28, 2026

Magnetic Levitation Coupled with Portable Imaging and Analysis for Disease Diagnostics
Published on: February 19, 2017
Red cell distribution width predicts mortality in infective endocarditis.
Yesim Guray1, Esra Gucuk Ipek1, Umit Guray1
1Yuksek Ihtisas Education and Research Hospital, Department of Cardiology, Ankara, Turkey.
Red cell distribution width (RDW) can predict mortality in patients with infective endocarditis (IE). Higher RDW levels are associated with increased risk of death within one year, offering a new biomarker for patient outcomes.
Area of Science:
- Cardiology
- Hematology
- Clinical Biomarkers
Background:
- Infective endocarditis (IE) presents significant morbidity and mortality.
- Red cell distribution width (RDW) is an emerging biomarker for adverse outcomes in various conditions.
Purpose of the Study:
- To investigate the association between RDW and 1-year survival in patients diagnosed with IE.
- Evaluate RDW as a predictive marker for mortality in IE patients.
Main Methods:
- Retrospective analysis of clinical data from two tertiary centers for patients with definite IE.
- Evaluation of clinical, echocardiographic, and biochemical variables, including RDW.
- Determination of 1-year survival status post-index hospitalization.
Main Results:
- A cohort of 100 patients with definite IE was analyzed.
- An RDW cutoff of 15.3% was identified as optimal for predicting mortality (AUC 0.70, P=0.001).
- Multivariable analysis identified RDW > 15.3% (HR 3.07), renal failure (HR 3.21), and heart failure (HR 2.77) as independent predictors of 1-year mortality.
Conclusions:
- Mortality remains high among patients with infective endocarditis.
- RDW demonstrates potential as a valuable biomarker for predicting 1-year survival in IE patients.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis I: Introduction
Endocarditis IV: Nursing Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Endocarditis III: Medical Management

